Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
Abstract: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM. We describe...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925001594 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169028884037632 |
|---|---|
| author | E. Bridget Kim Jack E. Malespini Matthew Lei Samuel S. Han Cole W. Minsky Andrew R. Branagan Elizabeth K. O’Donnell Diana Cirstea Noopur S. Raje Andrew J. Yee |
| author_facet | E. Bridget Kim Jack E. Malespini Matthew Lei Samuel S. Han Cole W. Minsky Andrew R. Branagan Elizabeth K. O’Donnell Diana Cirstea Noopur S. Raje Andrew J. Yee |
| author_sort | E. Bridget Kim |
| collection | DOAJ |
| description | Abstract: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM. We describe the effects of daratumumab-based therapy in 20 patients admitted with a new diagnosis of MM and AKI with a median creatinine of 6.5 mg/dL. All patients (100%) achieved serum free light chain (sFLC) reduction ≥50% within the first cycle, with a median time to sFLC reduction ≥50% of 3 days (95% confidence interval [CI], 3-7). Of 17 patients, 15 (88%) achieved sFLC reduction ≤500 mg/L after 1 cycle of treatment. The median time to sFLC reduction ≤500 mg/L was 14.5 days (95% CI, 9-49). The overall renal response at 3 months was 85% (n = 17), with complete, partial, and minor responses in 50% (n = 10), 10% (n = 2), and 25% (n = 5), respectively. Of the 9 patients who required dialysis at presentation, 4 of 7 (57.1%) and 6 of 7 (85.7%) were dialysis independent at 3 and 12 months, respectively. Hematologic overall response rate was 100%, with very good partial response (VGPR) in 90%. With a median follow-up of 25 months, progression-free survival was 46.5 months (95% CI, 11.9 to not reached), and the 2-year overall survival was 83.7% (95% CI, 68.4-100). These findings highlight the importance of early initiation of daratumumab-based treatment in patients with MM and AKI to induce rapid and significant reductions in sFLCs, improve renal outcomes, and provide an approach without plasmapheresis. |
| format | Article |
| id | doaj-art-44ddbd0f4e124d7c88db0e2927b7d976 |
| institution | OA Journals |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-44ddbd0f4e124d7c88db0e2927b7d9762025-08-20T02:20:51ZengElsevierBlood Advances2473-95292025-07-019133129313510.1182/bloodadvances.2025015901Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injuryE. Bridget Kim0Jack E. Malespini1Matthew Lei2Samuel S. Han3Cole W. Minsky4Andrew R. Branagan5Elizabeth K. O’Donnell6Diana Cirstea7Noopur S. Raje8Andrew J. Yee9Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MA; Correspondence: Andrew J. Yee, Massachusetts General Hospital Cancer Center Boston, 55 Fruit St, Boston, MA 02114;Abstract: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM. We describe the effects of daratumumab-based therapy in 20 patients admitted with a new diagnosis of MM and AKI with a median creatinine of 6.5 mg/dL. All patients (100%) achieved serum free light chain (sFLC) reduction ≥50% within the first cycle, with a median time to sFLC reduction ≥50% of 3 days (95% confidence interval [CI], 3-7). Of 17 patients, 15 (88%) achieved sFLC reduction ≤500 mg/L after 1 cycle of treatment. The median time to sFLC reduction ≤500 mg/L was 14.5 days (95% CI, 9-49). The overall renal response at 3 months was 85% (n = 17), with complete, partial, and minor responses in 50% (n = 10), 10% (n = 2), and 25% (n = 5), respectively. Of the 9 patients who required dialysis at presentation, 4 of 7 (57.1%) and 6 of 7 (85.7%) were dialysis independent at 3 and 12 months, respectively. Hematologic overall response rate was 100%, with very good partial response (VGPR) in 90%. With a median follow-up of 25 months, progression-free survival was 46.5 months (95% CI, 11.9 to not reached), and the 2-year overall survival was 83.7% (95% CI, 68.4-100). These findings highlight the importance of early initiation of daratumumab-based treatment in patients with MM and AKI to induce rapid and significant reductions in sFLCs, improve renal outcomes, and provide an approach without plasmapheresis.http://www.sciencedirect.com/science/article/pii/S2473952925001594 |
| spellingShingle | E. Bridget Kim Jack E. Malespini Matthew Lei Samuel S. Han Cole W. Minsky Andrew R. Branagan Elizabeth K. O’Donnell Diana Cirstea Noopur S. Raje Andrew J. Yee Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury Blood Advances |
| title | Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury |
| title_full | Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury |
| title_fullStr | Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury |
| title_full_unstemmed | Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury |
| title_short | Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury |
| title_sort | early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury |
| url | http://www.sciencedirect.com/science/article/pii/S2473952925001594 |
| work_keys_str_mv | AT ebridgetkim earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT jackemalespini earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT matthewlei earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT samuelshan earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT colewminsky earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT andrewrbranagan earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT elizabethkodonnell earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT dianacirstea earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT noopursraje earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury AT andrewjyee earlydaratumumabtherapyimprovesrenaloutcomesinnewlydiagnosedpatientswithmyelomaadmittedwithkidneyinjury |